Skip to main content
RECCE PHARMACEUTICALS LTD logo

RECCE PHARMACEUTICALS LTD — Investor Relations & Filings

Ticker · RCE ISIN · AU000000RCE5 LEI · 549300TKQWXKEHP10T28 ASX Manufacturing
Open in API
Filings indexed 687 across all filing types
Latest filing 2021-03-09 Investor Presentation
Country AU Australia
Listing ASX RCE

About RECCE PHARMACEUTICALS LTD

https://www.recce.com.au

Recce Pharmaceuticals Ltd is dedicated to the development and commercialization of a new class of synthetic anti-infectives designed to address the global challenge of antimicrobial resistance. The company's lead compound, RECCE® 327, is a broad-spectrum synthetic antibiotic engineered with a unique mechanism of action to combat hyper-mutating bacteria, including both Gram-positive and Gram-negative species. This technology is specifically formulated to maintain efficacy over repeated use, targeting critical medical needs such as sepsis, burn wound infections, and urinary tract infections. By utilizing a proprietary synthetic polymer-based platform, the company aims to disrupt bacterial cellular processes in a manner that prevents the development of resistance, providing a potential solution for multi-drug resistant pathogens.

Recent filings

Filing Released Lang Actions
Recce Presenting at H.C. Wainwright Life Sciences Conference 33 pages 3.6MB
Investor Presentation Classification · 95% confidence The document is an ASX announcement dated March 2021 from Recce Pharmaceuticals about the CEO presenting at the H.C. Wainwright Global Life Sciences Conference. It includes an overview of the company's business, pipeline, corporate updates, capital structure, board and management details, and product information. The text mentions that a copy of the presentation is attached and available on the company's website. The content is primarily a presentation aimed at investors and analysts, focusing on company strategy, pipeline, and market position. There are no financial statements or detailed financial results included, nor is this a regulatory filing or certification. The document is lengthy (15,000 characters) and contains detailed presentation material rather than a brief announcement or a report publication notice. Therefore, the best classification is Investor Presentation (IP).
2021-03-09 English
Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange 2 pages 340.0KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement about Recce Pharmaceuticals dual listing on the Frankfurt Stock Exchange. It discusses the trading of existing securities, no capital raising, and the strategic benefits of the dual listing. There is no financial data, no detailed report, no management discussion, or earnings information. The document is an announcement of a capital market event related to the company's capital structure and trading status. Therefore, it fits best under Capital/Financing Update (CAP). The document length is 3640 characters, which is consistent with an announcement rather than a full report.
2021-03-07 English
Appendix 4D and Half Yearly Report 26 pages 461.7KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'INTERIM REPORT FOR THE HALF YEAR ENDED 31 DECEMBER 2020' and contains detailed financial statements such as Consolidated Statement of Profit or Loss, Statement of Financial Position, and Notes to the Financial Statements. It includes a Directors' Report, Auditor's Independence Declaration, and an Independent Auditor's Review Report. The content covers financial results, operational highlights, and clinical progress for the half-year period ending 31 December 2020. This matches the characteristics of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year and contains substantive financial data and analysis. The document is about 15,000 characters long, indicating it is a full report rather than a brief announcement or certification. Therefore, the correct classification is IR (Interim / Quarterly Report).
2021-02-24 English
Appendix 2A 15 pages 277.0KB
Capital/Financing Update Classification · 100% confidence The document is an Appendix 2A form, which is an application for quotation of securities on the ASX (Australian Securities Exchange). It details the issuance of securities due to options being exercised or convertible securities converted, including specifics such as the number of securities and dates. This type of document is a regulatory announcement related to capital changes, specifically the quotation of new securities following conversion or exercise of options. It is not a financial report, earnings release, or management discussion, but rather a formal notification of a capital/financing event. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and content confirm it is a substantive announcement, not merely a report publication announcement or a regulatory filing fallback.
2021-02-24 English
Cleansing Statement 1 page 243.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement titled 'Cleansing notice under section 708A of the Corporations Act'. It discusses the issuance of fully paid ordinary shares and compliance with specific sections of the Corporations Act. The content is regulatory in nature, related to share issuance disclosure exemptions, but does not contain financial statements or detailed financial data. The document length is short (1199 characters) and it serves as a formal notice rather than a full report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-02-24 English
Change of Director's Interest Notice 3 pages 219.6KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including shares and unlisted options acquired. The document is a formal notification of insider share transactions by a director, which aligns with the definition of Director's Dealing filings. The document length is 4410 characters, which is consistent with a detailed insider transaction notice rather than a full financial report or announcement. There is no indication of financial results, management discussion, or other report types. Therefore, the correct classification is Director's Dealing (DIRS).
2021-02-24 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.